NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01 2024 - 4:01PM
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or
the “Company”), a late-stage, clinical biopharmaceutical company
developing oral, non-statin medicines for patients at risk of
cardiovascular disease with elevated low-density lipoprotein
cholesterol (“LDL-C”), for whom existing therapies are not
sufficiently effective or well-tolerated, today announced that
Michael Davidson, M.D., chief executive officer of NewAmsterdam
Pharma and Ian Somaiya, chief financial officer, will participate
in a fireside chat at the Guggenheim Healthcare Talks 6th Annual
Biotechnology Conference on Wednesday, February 7, 2024 at 1:00
p.m. ET.
A live webcast of the fireside chat will be available through
the investor relations section of the NewAmsterdam Pharma website
at ir.newamsterdampharma.com. Following the live webcast, an
archived replay will be available on the Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage
biopharmaceutical company whose mission is to improve patient care
in populations with metabolic diseases where currently approved
therapies have not been adequate or well tolerated. We seek to fill
a significant unmet need for a safe, well tolerated and convenient
LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is
investigating obicetrapib, an oral, low-dose and once-daily CETP
inhibitor, alone or as a fixed-dose combination with ezetimibe, as
preferred LDL-C lowering therapies to be used as an adjunct to
statin therapy for patients at risk of CVD with elevated LDL-C, for
whom existing therapies are not sufficiently effective or well
tolerated.
Company ContactMatthew PhilippeP:
1-917-882-7512matthew.philippe@newamsterdampharma.com
Media ContactSpectrum Science on behalf of
NewAmsterdamJen GordonP:
1-202-957-7795jgordon@spectrumscience.com
Investor ContactStern Investor Relations on
behalf of NewAmsterdamHannah DeresiewiczP:
1-212-362-1200hannah.deresiewicz@sternir.com
NewAmsterdam Pharma Comp... (NASDAQ:NAMS)
Historical Stock Chart
From Jul 2024 to Aug 2024
NewAmsterdam Pharma Comp... (NASDAQ:NAMS)
Historical Stock Chart
From Aug 2023 to Aug 2024